Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615144 | 0.83 | SMN1; SMN2 (0.42) | MEN1KMT2AEPHX2NR1H4HDAC6 | |
| SCHEMBL18384364 | 0.83 | SMN1; SMN2 (0.44) | MEN1KMT2AEPHX2NR1H4HDAC6 | |
| SCHEMBL16192938 | 0.79 | KMT2A (0.40) | MEN1KMT2AHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL43720 | 0.75 | TSHR (0.34) | — | |
| SCHEMBL14730974 | 0.74 | EPHX2 (0.46) | EPHX2NR1H4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL16784522 | 0.74 | LMNA (0.47) | EPHX2NR1H4ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL16784533 | 0.74 | EPHX2 (0.41) | EPHX2NR1H4HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL30483144 | 0.73 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL19662527 | 0.71 | MAPK1 (0.46) | MEN1KMT2AHDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL768869 | 0.71 | TSHR (0.45) | KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020141930-A1 | DRUG DELIVERY SYSTEM USING PH-DEPENDENT CELL-PENETRATING PEPTIDES, AND COMPOSITE THEREOF WITH DRUG | 김성천 | 2020-07-09 | — | — | WO | disclosed |
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | AGO2, HNRNPH3, HCLS1 | MEN1 2736/4885KMT2A 337/4885EPHX2 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.